PureTech Health's founded entity Seaport Therapeutics appointed Dr Sharon Mates to its board, tapping the leader who guided Intra‑Cellular Therapies from discovery through commercialisation and a $14.6bn sale to Johnson & Johnson after CAPLYTA exceeded $1.5bn in sales.
Seaport Therapeutics, a clinical‑stage company developing oral neuropsychiatric medicines using its Glyph platform, said the appointment bolsters its leadership as it advances programmes for depression, anxiety and other neuropsychiatric disorders.
"Her significant experience, intellectual curiosity, deep industry relationships, and genuine appreciation for our patient‑centered approach will meaningfully support Seaport's mission to develop life‑changing treatments for patients with depression, anxiety, and other neuropsychiatric disorders," said Daphne Zohar, Founder and Chief Executive Officer of Seaport Therapeutics.
Dr Mates co‑founded and led Intra‑Cellular from 2002 until its 2025 acquisition and brings decades of neuropsychiatry drug‑development and commercialisation experience to Seaport's board. She also serves on the boards of Medincell and Benitec and is forming a new company in inflammation and metabolism, adding governance and sector relationships to Seaport's investor and scientific network.
